Member Info for DanRey

Fantastic news, especially on the previous dosed patients.

Drutor I would have thought patient confidentiality would be priority with only results shared within strict legal guidelines/arrangements.

Although I wish the Scientists well and thank them for getting us to the stage we are now at I wondered if maybe future involvement with larger pharmaceuticals would not require us having our scientists and maybe part of a bigger picture. Maybe there are things going on behind the scenes to advance us financially now we are dosing patients. Only a thought and not based on anything other than hope.

Mr India It is good that you have confidence to invest further. I would just hope if this good news is occurring that the rest of us share holders would receive this information via an RNS and we would at last have the confidence to invest further or at least one day hope we will recoup our long term investment. Kind regards.

Mr India just out of interest how do you know Patient. 1and 2 are surviving and thriving, obviously I hope they are and how do you know about the funding Vlad is arranging, obviously I hope he is. Kind regards.

From observation It often seems when we get a total voting rights RNS a further shares issue follows not long after.

1.56 to buy 1.54 to sell on Halifax. Another fair sized drop. ? further funding again.

I believe a lot of sells are buys but showing as sells as under the mid price.

Congratulations to Hemo and the team on their research and science that has led to this point. Obviously the hope this brings for treating many cancer patients in the future. As a shareholder my hope is they can finally start to improve the business side of things from here and as long term holders we can be rewarded for our patience too.

At no point am I questioning anybodies scientific knowledge and we would all love to see an end to cancer however Hemo is not a cancer charity it is a business funded by shareholders and the market. We who invest hope to make money. That is capitalism. I know we make our investment own investment decisions and must own them. I would say as a share holder we are entitled to disagree with board decisions and moan with the bad and celebrate the good. Shorters may be responsible for the decline but Vlads business plan has made it easy for them. Mint and the recent raise perfect examples. He seems to follow the same plan each time. As has been said there may have been other options on the table. I don’t know if that’s the case but if so gives us shareholders the right to feel disgruntled. I don’t want to argue and I always respect other opinions and believe in dialogue.

Vlad obviously only cares about his great experiment and we the shareholders are only the tool to get it to market. He has always played the same game release information then raise. We have been here long enough to know that. I am just bitter that I believed the science may see me a return on my investment. It is hard to sell at a loss while hoping. Hemo has been like a relationship you know is wrong but it’s difficult to walk away. Almost like self harm.

I was hoping it was a misprint. People who have been here a long time should not be surprised by this. Just continue of clinical advance and then raise/dilution.

Feels like this is being held back. Fair amount of buys and large spread?

It is wonderful news about the first injection and congratulations to Hemo on the Science behind it. Maybe the lack of rise is down to continued concerns about the need for finance and Hemo long history of raising following clinical advance. It feels like those with an appetite for risk and deep pockets are in the best position and you will undoubtedly prevail. As a long term small holder who has watched there holding erode buying more is not an option and there maybe not the masses with the disposable income to invest. A large group of potential holders have already done so privately. I hope you don’t take this as a negative spin but just as a reason why I wondered why we didn’t rise further yesterday on such important news.

Octp delisted today stating market undervaluation and difficulty for biotech to raise funds. Seems that our sector is struggling in this current market.

Couldn’t agree more.

I wonder if another big delayed sell will go through again at some point as the buying action seems to be taking us nowhere.

The news has had no effect on the market. Maybe already factored in only valuing OCTP at around 3.5 million. Shame as valued at 10 million+ last year without a product at phase 1. Think it’s the same across most Pharma at the moment.

Supposedly just done one. Doesn’t feel like we are going anywhere. Wondered why they didn’t move forward with our first product to phase 2 than another phase 1?

Arthur, OCTP